Titre : | Effect of cannabidiol and Delta9-tetrahydrocannabinol on driving performance: A randomized clinical trial (2020) |
Auteurs : | T. R. ARKELL ; F. VINCKENBOSCH ; R. C. KEVIN ; E. L. THEUNISSEN ; I. S. MCGREGOR ; J. G. RAMAEKERS |
Type de document : | Article : Périodique |
Dans : | Journal of the American Medical Association (Vol.324, n°21, December 1, 2020) |
Article en page(s) : | 2177-2186 |
Note générale : |
Editorial: Cole T.B., Saitz R. Cannabis and impaired driving. JAMA, 2020, Vol. 324, n° 21, p. 2163-2164. https://doi.org/10.1001/jama.2020.18544
Rubin R. Driving under the influence of CBD or THC - Is there a difference? JAMA, 2020, Vol. 324, n° 21, p. 2144-2145. https://doi.org/10.1001/jama.2020.22181 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés CANNABINOIDES ; CANNABIDIOL ; TETRAHYDROCANNABINOL ; CONDUITE DE VEHICULE ; ETUDE RANDOMISEE ; CANNABIS ; PERFORMANCE ; COMPARAISON ; TEST ; COGNITION ; PSYCHOMOTRICITEThésaurus géographique PAYS-BAS |
Résumé : |
Question: What is the magnitude and duration of driving impairment following vaporization of cannabis containing varying concentrations of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD)?
Findings: In this crossover clinical trial that included 26 healthy participants who underwent on-road driving tests, the standard deviation of lateral position (SDLP, a measure of lane weaving, swerving, and overcorrecting) at 40 to 100 minutes following vaporized consumption was 18.21 cm for CBD-dominant cannabis, 20.59 cm for THC-dominant cannabis, 21.09 cm for THC/CBD-equivalent cannabis, and was 18.26 cm for placebo. At 240 to 300 minutes, the SDLP was 19.03 cm for CBD-dominant cannabis, 20.59 cm for THC-dominant cannabis, 19.88 cm for THC/CBD-equivalent cannabis, and 19.37 cm for placebo. Compared with placebo, SDLP with THC-dominant and THC/CBD-equivalent cannabis was significantly greater at 40 to 100 minutes but not 240 to 300 minutes after consumption; there were no significant differences between CBD-dominant cannabis and placebo. Meaning: Although this study did not find statistically significant differences in driving performance during experimental on-road driving tests between CBD-dominant cannabis and placebo, the effect size may not have excluded clinically important impairment, and the doses tested may not necessarily represent common usage. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 36 |
Affiliation : | Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia |
Accueil